Tibet Rhodiola Pharmaceutical Holding Co (600211) — Cash Flow-to-Debt Ratio
Tibet Rhodiola Pharmaceutical Holding Co (600211) has a Cash Flow-to-Debt Ratio of 0.14x as of December 2025, meaning its operating cash flow of CN¥297.86 Million could theoretically repay 0% of its total liabilities (CN¥2.10 Billion) in one year. See free cash flow generation of Tibet Rhodiola Pharmaceutical Holding Co to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tibet Rhodiola Pharmaceutical Holding Co Cash Flow-to-Debt Ratio (1999–2025)
Historical debt coverage capacity for Tibet Rhodiola Pharmaceutical Holding Co across 27 annual periods. Also explore Tibet Rhodiola Pharmaceutical Holding Co (600211) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)
Year-by-year debt coverage analysis for Tibet Rhodiola Pharmaceutical Holding Co. For market capitalisation and broader financial context, see 600211 market cap.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.49x | CN¥1.03 Billion | CN¥2.10 Billion | ▼ -60.9% |
| 2024 | 1.25x | CN¥994.79 Million | CN¥795.23 Million | ▲ +40.3% |
| 2023 | 0.89x | CN¥1.08 Billion | CN¥1.21 Billion | ▲ +13.8% |
| 2022 | 0.78x | CN¥837.38 Million | CN¥1.07 Billion | ▲ +147.5% |
| 2021 | 0.32x | CN¥366.53 Million | CN¥1.16 Billion | ▼ -73.7% |
| 2020 | 1.20x | CN¥428.17 Million | CN¥355.91 Million | ▼ -21.3% |
| 2019 | 1.53x | CN¥489.59 Million | CN¥320.44 Million | ▲ +45.2% |
| 2018 | 1.05x | CN¥289.22 Million | CN¥274.89 Million | ▲ +227.4% |
| 2017 | 0.32x | CN¥91.46 Million | CN¥284.64 Million | ▲ +109.6% |
| 2016 | 0.15x | CN¥250.21 Million | CN¥1.63 Billion | ▼ -74.8% |
| 2015 | 0.61x | CN¥133.93 Million | CN¥220.43 Million | ▲ +371.7% |
| 2014 | -0.22x | CN¥-141.40 Million | CN¥632.26 Million | ▼ -159.1% |
| 2013 | 0.38x | CN¥279.22 Million | CN¥738.26 Million | ▲ +209.4% |
| 2012 | 0.12x | CN¥56.20 Million | CN¥459.72 Million | ▲ +337.8% |
| 2011 | 0.03x | CN¥12.09 Million | CN¥432.93 Million | ▲ +504.5% |
| 2010 | 0.00x | CN¥1.90 Million | CN¥411.28 Million | ▼ -88.5% |
| 2009 | 0.04x | CN¥17.88 Million | CN¥443.70 Million | ▲ +3.4% |
| 2008 | 0.04x | CN¥21.46 Million | CN¥550.51 Million | ▲ +218.8% |
| 2007 | -0.03x | CN¥-18.30 Million | CN¥557.68 Million | ▼ -145.9% |
| 2006 | 0.07x | CN¥33.63 Million | CN¥470.56 Million | ▲ +61.4% |
| 2005 | 0.04x | CN¥18.92 Million | CN¥427.37 Million | ▼ -43.8% |
| 2004 | 0.08x | CN¥26.90 Million | CN¥341.74 Million | ▼ -45.0% |
| 2003 | 0.14x | CN¥47.20 Million | CN¥329.82 Million | ▲ +36.9% |
| 2002 | 0.10x | CN¥32.85 Million | CN¥314.23 Million | ▲ +36.4% |
| 2001 | 0.08x | CN¥15.47 Million | CN¥201.82 Million | ▼ -53.0% |
| 2000 | 0.16x | CN¥20.55 Million | CN¥126.01 Million | ▲ +239.2% |
| 1999 | 0.05x | CN¥2.25 Million | CN¥46.73 Million | — |